Speaker illustration

Mrs Julia Moellmann

RWTH University Hospital Aachen, Aachen (Germany)

The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis.

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardiac Hypertrophy

Session: Congress committee e-posters choice in basic science

Thumbnail

Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism.

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Targeting reverse remodelling in heart failure

Thumbnail

Myocardial infarction is sufficient to increase GLP-1 secretion leading to improved left ventricular contractility and mitochondrial respiratory capacity

Event: Heart Failure 2018

Topic: Pathophysiology and Mechanisms

Session: Acute Heart Failure – Pathophysiology and Mechanisms

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb